Investigating BMAL1-RNA interactions and their roles in circadian rhythms
- Institution
- BOSTON CHILDREN'S HOSPITAL, MA
- Principal investigator
- Suil Kim
- Funding
- $81K
- Duration
- 2025–2026
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY The circadian clock is an endogenous timekeeping mechanism that drives daily rhythms in gene expression, physiology, and behavior. The key components of the circadian clock in mammals are transcription factors and regulators that drive rhythmic transcription. Recently, RNA has emerged as a biophysical modulator of transcription factors and other chromatin-associated factors via direct interactions. However, how these RNA- protein interactions might shape circadian rhythms remains unexplored. My preliminary data suggests that a master circadian transcription factor BMAL1 directly interacts with RNA. This led to the hypothesis that BMAL1- RNA interactions modulate circadian rhythms. To test this hypothesis, I propose the following aims: (1) Identify and characterize BMAL1-binding RNAs, (2) Define structural determinants of BMAL1-RNA interaction and determine their role in regulating circadian transcription and translation. I will carry out this study using a variety of molecular biology and genomic techniques, including a biochemical assay to capture RNA-protein interactions, RNA sequencing, and genetic manipulation. This work will uncover a novel modulatory mechanism of circadian rhythms and provide a foundation for studying the mechanistic link between the circadian clock and a wide range of RNA-mediated cellular functions. This fellowship will provide an excellent opportunity to gain expertise in molecular biology and RNA-protein interaction. This will prepare me to become an independent academic investigator studying circadian rhythms at multiple levels.
LOADING MOONBASE SCORE
Questions for BOSTON CHILDREN'S HOSPITAL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Boston Children'S Hospital67
A 90 day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children with Short Bowel Syndrome who are Dependent on Parenteral Nutrition
Mark Puder · $365K · 2021–2028
- NIH · Boston Children'S Hospital64
Motion and Distortion Robust Diffusion Weighted Imaging Sequences for Pediatric Patients
Onur Afacan · $398K · 2022–2027
- NIH · Boston Children'S Hospital51
Insulin Regulation of Hepatic Function via Zone-Specific Transcriptional Programs
Sudha B Biddinger · $500K · 2021–2027